GlassScriptPhysician profile
Don F King
NPI 1811073430
$13,442.15
in general payments reported to CMS, 2019-2025
30 companies · $3,363 in 2025
The $3,363 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,826 · 2020: $456 · 2021: $653 · 2022: $1,785 · 2023: $3,216 · 2024: $2,142 · 2025: $3,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,620 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,619.60 |
| Education | $101.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,881.49 | 2020-2025 | Dupixent, Libtayo |
| Abbvie INC. | $1,708.79 | 2019-2025 | |
| Janssen Biotech, INC. | $1,321.42 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $1,110.73 | 2020-2025 | |
| Pfizer INC. | $1,101.05 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $976.89 | 2019-2024 | Siliq, Jublia, Arazlo |
| Leo Pharma INC. | $844.57 | 2020-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $619.94 | 2019-2025 | Winlevi, Absorica Ld, Odomzo |
| Amgen INC. | $578.01 | 2020-2024 | Otezla |
| Novartis Pharmaceuticals Corporation | $522.63 | 2019-2025 | |
| Ucb, INC. | $442.57 | 2019-2025 | Bimzelx |
| Incyte Corporation | $384.52 | 2023-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $381.76 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $325.13 | 2020-2025 | Nemluvio |
| Celgene Corporation | $193.76 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $175.35 | 2019-2025 | Taltz, Ebglyss |
| Ethicon US, LLC | $151.47 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.82 | 2022-2025 | Spevigo |
| Dermavant Sciences, INC. | $122.11 | 2023-2024 | Vtama |
| Stemline Therapeutics INC. | $86.05 | 2019 | |
| Arcutis Biotherapeutics, INC. | $59.12 | 2023-2025 | Zoryve |
| Mallinckrodt Hospital Products INC. | $48.02 | 2025 | Acthar |
| Regeneron Pharmaceuticals, INC. | $45.00 | 2019 | |
| Kyowa Kirin, INC. | $43.84 | 2021-2024 | Poteligeo |
| Organogenesis INC. | $43.55 | 2024 | Affinity |
| Leo Pharma As | $37.90 | 2021 | |
| Journey Medical Corporation | $37.74 | 2022-2023 | |
| Dermira, INC. | $20.14 | 2020 | |
| Merck Sharp & Dohme LLC | $17.44 | 2019 | |
| Organon LLC | $11.34 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.